@techreport{oai:mie-u.repo.nii.ac.jp:00015266,
 author = {土肥, 薫 and DOHI, KAORU and 伊藤, 正明 and Ito, Masaaki and 岡本, 隆二 and Okamoto, Ryuji and 片山, 鑑 and Katayama, Kan},
 month = {May},
 note = {application/pdf, Dahl食塩感受性高血圧ラットを低食塩群(n=10)、高食塩群(n=10)、高食塩＋ SGLT2阻害薬 (ipragliflozin）群（n=10）、高食塩＋ARB(losartan)群(n=10)、高食塩＋SGLT2阻害薬＋ARB(n=10)群に振り分けた。併用投与群でのみ食塩感受性が改善した。併用投与群では単独治療に比べ腎硬化スコアの有意な改善を示し、心筋肥大ならびに線維化も改善所見が得られた。AT1R, NHE3およびNKCC2の蛋白発現がSGLT2阻害薬単独投与では低下しない一方で、併用療法では両者とも有意に抑制され、AT1R発現抑制作用に関してはARB単独投与よりもさらに優れていた。, Dahl salt-sensitive (DSS) hypertensive rats were treated orally for 8-weekswith normal salt diet (0.3% NaCl), high salt diet (8% NaCl), high salt diet with SGLT2 inhibitor(ipragliflozin 0.04%), high salt diet with ARB (losartan 0.05%), or high salt diet with combination treatment. Only the combination treatment lower blood pressure and improved salt-sensitivity. The combination treatment significantly ameliorated glomerulosclerosis, and reduced cardiomyocyte hypertrophy and perivascular fibrosis. Angiotensin II type 1 receptor (AT1R) protein expression level in the kidney was remarkably suppressed in the combination treatment group compared to the other high salt diet groups. The protein expression level of Na+/H+ exchanger isoform 3 and Na+-K+-Cl- cotransporter 2 were significantly decreased with losartan alone and combination with ipragliflozin., 2018年度～2020年度科学研究費補助金(基盤研究(C))研究成果報告書, 18K08101},
 title = {食塩感受性高血圧モデルにおけるSGLT2阻害の心不全進展抑制効果の検討},
 year = {2021},
 yomi = {ドヒ, カオル and イトウ, マサアキ and オカモト, リュウジ and カタヤマ, カン}
}